Navigation Links
Mylan Receives Final FDA Approvals for Generic Versions of Lamictal(R) Tablets and Lamictal(R) CD
Date:1/28/2009

PITTSBURGH, Jan. 28 /PRNewswire-FirstCall/ --Mylan Inc. (Nasdaq: MYL) today announced that its subsidiaries Mylan Pharmaceuticals Inc. and Genpharm ULC received final approvals from the U.S. Food and Drug Administration (FDA) for their Abbreviated New Drug Applications (ANDAs) for Lamotrigine Tablets. Genpharm also received final FDA approval for its ANDA for a separate Lamotrigine product, Lamotrigine Tablets Chewable Dispersible (CD).

Mylan Pharmaceuticals' and Genpharm's ANDAs were approved for the 25 mg, 100 mg, 150 mg and 200 mg strengths of the generic version of GlaxoSmithKline's Lamictal(R) Tablets. This product had annual U.S. sales of approximately $2.5 billion for the 12 months ending Sept. 30, 2008, for the same strengths according to IMS Health.

Genpharm's ANDA was approved for the 5 mg and 25 mg strengths of the generic version of GlaxoSmithKline's Lamictal(R) CD Tablets. This product had annual U.S. sales of approximately $91 million for the 12 months ending Sept. 30, 2008, for the same strengths according to IMS Health.

These products are used for the treatment of epilepsy and for maintenance treatment of bipolar I disorder. Mylan will distribute both products immediately and under the Mylan Pharmaceuticals label.

Mylan Inc., which provides products to customers in more than 140 countries and territories, ranks among the leading diversified generic and specialty pharmaceutical companies in the world. The company maintains one of the industry's broadest - and highest quality - product portfolios, supported by a robust product pipeline; owns a controlling interest in the world's third largest active pharmaceutical ingredient manufacturer; and operates a specialty business focused on respiratory and allergy therapies. For more information, please visit www.mylan.com.


'/>"/>
SOURCE Mylan Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Mylan Receives Final FDA Approval for Generic Version of Prilosec(R) Delayed-Release Capsules, 40 mg
2. U.S. Patent and Trademark Office Issues Mylans Specialty Division, Dey L.P., Three Additional Patents Protecting Perforomist(R) Inhalation Solution
3. Mylan to Present at the 27th Annual J.P. Morgan Healthcare Conference
4. Mylans Matrix Receives Final FDA Approval for the Generic Version of the Antiretroviral Zerit(R) Capsules
5. Mylan Announces Move to NASDAQ Stock Market
6. Mylan Announces Settlement Agreement with Novartis Related to Femara(R) First- to-File Opportunity
7. Mylan Receives Final FDA Approval for the Generic Version of the Antidepressant Sarafem(R) Pulvules(R) Capsules
8. Mylan Receives Final Approval for First-to-File Generic Version of Antiepileptic Keppra(R) and Launches Immediately
9. Mylan Declares Quarterly Preferred Stock Dividend
10. Mylans Matrix First-to-File on Generic Version of Vfend(R) Antifungal
11. Mylan to Retain Dey, L.P., Its Specialty Pharmaceutical Subsidiary
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... ... February 11, 2016 , ... ... Garrett Esq. as General Counsel. Garrett will focus on contract negotiations, corporate strategy ... privacy and security law, and best practices in data breaches for the Part ...
(Date:2/11/2016)... ... February 11, 2016 , ... Talix today announced that Clive ... be presenting at the 2016 HIMSS Annual Conference & Exhibition, taking place February ... session, “ Coding for Care: Using Data Analytics for Risk Adjustment ,” Dr. ...
(Date:2/11/2016)... , ... February 11, 2016 , ... Be Well ... office in the heart of Old Town at 108 South Columbus St, Suite 201, ... the highest level of medical care in the convenience of their homes, offices or ...
(Date:2/11/2016)... Southborough, MA (PRWEB) , ... February 11, 2016 , ... ... avoid overpaying for IT services, what questions to ask your IT consultant before signing ... them access to your computer network. , “With companies relying heavily on e-mail and ...
(Date:2/10/2016)... ... February 10, 2016 , ... Sherly Sulaiman, certified clinical ... of therapeutic sessions to help Los Angeles-area actors cope with rejection, improve their ... series, known as “Mindfulness for Actors and Artists,” has been featured in ...
Breaking Medicine News(10 mins):
(Date:2/11/2016)... Iowa , 11 de fevereiro de 2016 ... inauguração de sua fábrica de soroalbumina bovina (BSA ... Zelândia. A fábrica fica na Ilha Norte da ... "), desenvolvido e estabelecido na fábrica da Proliant ... . O projeto e instalação dos equipamentos ...
(Date:2/11/2016)... INDIANAPOLIS , Feb. 11, 2016 /PRNewswire/ ... people, but for those with type 1 diabetes, the ... students juggle class schedules, assignments and campus activities, they ... 1 diabetes. On top of that, many are living ... Diabetes Scholars Foundation (Foundation) Lilly Diabetes Tomorrow,s Leaders ...
(Date:2/11/2016)... ALBANY, New York , February 11, 2016 ... Research announces the release of a new research report, titled ... Growth, Trends and Forecast, 2013 - 2019". According to the ... expand at a 4.40% CAGR from 2013 to 2019, growing ... bn by 2019. --> --> ...
Breaking Medicine Technology: